Clinical Trial Update: Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease [Phase 4]

View source ↗

Summary

Phase 4 study evaluating high-dose intravenous immunoglobulin therapy for neonatal hyperbilirubinemia due to Rh hemolytic disease; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythroblastosis Fetalis
• Hyperbilirubinemia

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: Oswaldo Cruz Foundation | Conditions: Hyperbilirubinemia, Erythroblastosis, Fetal | Phase 4 | Status: COMPLETED | Results posted: 2016-01-08